Logo Image
Opinion|Videos|July 24, 2024

Examining the Evolving 3L Treatment Landscape for mCRC

Colorectal cancer specialists examine treatment sequencing strategies for third-line and subsequent therapy settings, while also evaluating regorafenib's efficacy and real-world outcomes.

Episodes in this series
  1. Briefly Given the latest approvals, is there a continued role for regorafenib in mCRC and how do real-world outcomes support its use? (Yisilamu P, et al. ASCO 2024. Abstract e15562)
  2. Dr Marshall to Panel:Let’s explore sequencing strategies for CRC in the 3L setting and beyond. Discuss how new data and other considerations impact treatment selection and sequencing.
  1. Dr Marshall to Panel: How would you describe your current approach to treatment sequencing?
  2. Dr Benson: How do you approach treating patients with fruquintinib from FRESCO and FRESCO-2 studies according to prior treatment sequence? (Bekaii-Saab T, et al. ASCO 2024. Abstract 3579.)
    1. Impact of prior bevacizumab
  3. Dr Fakih:Please comment on recently presented data from the SUNLIGHT study and the implications on your treatment sequencing:
    1. Impact of prior fluoropyrimidine (Fakih, et al. ASCO GI 2024. Abstract 114)
    2. Impact of prior bevacizumab
  4. Dr Cohen: Regorafenib and/or TAS-102 sequencing (Signorelli C, et al. ASCO 2024. Abstract e15553)

Related to this article

View more